Karyopharm Therapeutics Inc. entered into a Forbearance Agreement with its lenders and noteholders after failing to pay a $15.8 million term loan installment due on September 10, 2026, and missing cash interest payments on its 9.00% Convertible Senior Notes due 2028 and 2029. The agreement forbears creditors from exercising remedies for these defaults until October 15, 2026, or earlier upon bankruptcy, enforcement action, liquidity falling below $10 million, or FDA rejection of the sNDA for selinexor in myelofibrosis. To compensate lenders, Karyopharm issued a Fee Agreement requiring $20 million in fees paid via 20,000 shares of 0% convertible perpetual preferred stock at $1,000 per share, convertible into common stock at $1.62 per share. The company disclosed that absent additional funding or strategic transactions by October 15, it will be unable to continue as a going concern and may seek bankruptcy protection. Karyopharm Therapeutics Inc. operates in the biotechnology industry, developing and commercializing therapies for cancer.

On August 31, 2026, Karyopharm Therapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). The application seeks Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis, based on data from the Phase 3 SENTRY trial. Karyopharm requested Priority Review to potentially achieve a six-month review timeline. The company expects FDA feedback on filing acceptance and review timelines during the fourth quarter of 2026 following the standard 60-day filing review period. If approved via the Accelerated Approval pathway, long-term overall survival data from the SENTRY trial will be required to verify clinical benefit and support conversion to traditional approval. Karyopharm Therapeutics Inc. operates in the biotechnology industry, developing and commercializing therapies for cancer.

Karyopharm Therapeutics Inc. reported second quarter 2026 financial results with total revenue of $33.4 million and U.S. XPOVIO net product revenue of $30.8 million, compared to $37.9 million and $29.7 million respectively in the prior year period. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million and U.S. XPOVIO net product revenue guidance of $115 million to $130 million. Karyopharm announced it remains on track to submit a supplemental New Drug Application (sNDA) for selinexor in combination with ruxolitinib for myelofibrosis in August under the Accelerated Approval pathway, following FDA feedback that spleen volume reduction qualifies as a reasonably likely surrogate endpoint. The company is actively evaluating financing opportunities and strategic alternatives to extend its cash runway beyond September 2026, when a $15.8 million term loan payment is due. Karyopharm Therapeutics Inc. operates in the pharmaceutical industry, developing and commercializing novel cancer therapies.

Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy for TP53 wild-type endometrial cancer failed to meet the primary endpoint of progression-free survival, though a trend favoring selinexor was observed in the mITT population (median PFS 12.75 months vs 7.43 months; HR=0.76). The company plans to submit a supplemental New Drug Application for accelerated approval of selinexor with ruxolitinib for myelofibrosis in August 2026, following FDA feedback that spleen volume reduction qualifies as a surrogate endpoint, though the agency requested further discussion on data to support conversion to traditional approval. Additionally, Karyopharm is exploring potential financing transactions and strategic alternatives with Centerview Partners to extend its cash runway. The company operates in the biotechnology industry, developing and commercializing therapies for cancer and hematologic diseases.

Karyopharm Therapeutics Inc. implemented a 2026 Leadership Cash Retention Program to incentivize key employees during upcoming meaningful catalysts. The program replaces previously guaranteed 2026 Annual Bonus Plan amounts, providing lump sum cash retention awards to CEO Richard Paulson ($1,725,000), EVP Chief Development Officer Stuart Poulton ($640,000), Dr. Reshma Rangwala ($725,000), and CFO Lori Macomber ($625,000). Karyopharm Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for cancer and related diseases.